"This approach was recently shown by the S$6m investment in...

"This approach was recently shown by the S$6m investment in PrIME Biologics which valued that business at S$60m (A$46m),"

Congratulations for the Restructures Board and Company!

The restructures further clearly indicates the NSP's growth strategy and pave the way to move into ASX 300 (MC $100m) as of NSP's all the time target!

The key points I got from the announcements are:

1, NSP shareholders will be free carried 50% interests of each NSP subsidiaries and no funding requested from SHs.

2,Each subsidiary will solve the funding by itself, so far PrIME already get $4.6m, Spermgen project will be the next soon.

3, "To this end the Company is evaluating similar investment possibilities for the SpermSep application of the PrIME technology." As offers have been received,the external funding could be finalized soon. I reckon the finding is circa $5m for 50% of Spermgen project (vs current MC 8m)

4, "NuSep has established an external valuation which is significantly above the total value of NuSep, and thereby
unlocking some of the PrIME value."

Broker's valuation report will be released soon!

I am interested to see whether the broker's valuation is in line with my reckon--26-28C current fair value, 66c-mid term unrisked value per share.

time will tell, DYOR and all the best!